426 related articles for article (PubMed ID: 26053486)
1. Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Fermér C; Nilsson O; Seppänen H; Haglund C
PLoS One; 2015; 10(6):e0129012. PubMed ID: 26053486
[TBL] [Abstract][Full Text] [Related]
2. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
[TBL] [Abstract][Full Text] [Related]
3. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
4. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
5. Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients.
Guo S; Jing W; Hu X; Zhou X; Liu L; Zhu M; Yin F; Chen R; Zhao J; Guo Y
Int J Cancer; 2014 Mar; 134(6):1369-78. PubMed ID: 24037692
[TBL] [Abstract][Full Text] [Related]
6. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
[TBL] [Abstract][Full Text] [Related]
7. Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.
Zheng J; Huang S; Huang Y; Song L; Yin Y; Kong W; Chen X; Ouyang X
Tumour Biol; 2016 Jun; 37(6):7853-9. PubMed ID: 26695153
[TBL] [Abstract][Full Text] [Related]
8. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
9. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis.
Neuzillet C; Couvelard A; Tijeras-Raballand A; de Mestier L; de Gramont A; Bédossa P; Paradis V; Sauvanet A; Bachet JB; Ruszniewski P; Raymond E; Hammel P; Cros J
Histopathology; 2015 Nov; 67(5):664-76. PubMed ID: 25809563
[TBL] [Abstract][Full Text] [Related]
10. High expression of delta-like ligand 4 predicts poor prognosis after curative resection for pancreatic cancer.
Chen HT; Cai QC; Zheng JM; Man XH; Jiang H; Song B; Jin G; Zhu W; Li ZS
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S464-74. PubMed ID: 21822553
[TBL] [Abstract][Full Text] [Related]
11. Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma.
Yao H; Yang Z; Liu Z; Miao X; Yang L; Li D; Zou Q; Yuan Y
Cancer Biomark; 2016; 17(4):397-404. PubMed ID: 27689616
[TBL] [Abstract][Full Text] [Related]
12. Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer.
Eurola A; Ristimäki A; Mustonen H; Nurmi AM; Hagström J; Haglund C; Seppänen H
Sci Rep; 2021 May; 11(1):9896. PubMed ID: 33972616
[TBL] [Abstract][Full Text] [Related]
13. Low expression of IGFBP7 is associated with poor outcome of pancreatic ductal adenocarcinoma.
An W; Ben QW; Chen HT; Zheng JM; Huang L; Li GX; Li ZS
Ann Surg Oncol; 2012 Nov; 19(12):3971-8. PubMed ID: 22622471
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of FZD1 and CAIX are Associated with Invasion, Metastasis, and Poor-Prognosis of the Pancreatic Ductal Adenocarcinoma.
Yang L; Yang Z; Li D; Liu Z; Zou Q; Yuan Y; Xu H
Pathol Oncol Res; 2018 Oct; 24(4):899-906. PubMed ID: 28921449
[TBL] [Abstract][Full Text] [Related]
15. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z
Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of B2M and loss of ALK7 expression are associated with invasion, metastasis, and poor-prognosis of the pancreatic ductal adenocarcinoma.
Liu C; Yang Z; Li D; Liu Z; Miao X; Yang L; Zou Q; Yuan Y
Cancer Biomark; 2015; 15(6):735-43. PubMed ID: 26406402
[TBL] [Abstract][Full Text] [Related]
17. Positive expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic ductal adenocarcinoma.
Ben QW; Wang JC; Liu J; Zhu Y; Yuan F; Yao WY; Yuan YZ
Ann Surg Oncol; 2010 Aug; 17(8):2213-21. PubMed ID: 20162456
[TBL] [Abstract][Full Text] [Related]
18. Identification of ANXA1 as a lymphatic metastasis and poor prognostic factor in pancreatic ductal adenocarcinoma.
Liu QH; Shi ML; Bai J; Zheng JN
Asian Pac J Cancer Prev; 2015; 16(7):2719-24. PubMed ID: 25854353
[TBL] [Abstract][Full Text] [Related]
19. Podocalyxin is a marker of poor prognosis in colorectal cancer.
Kaprio T; Fermér C; Hagström J; Mustonen H; Böckelman C; Nilsson O; Haglund C
BMC Cancer; 2014 Jul; 14():493. PubMed ID: 25004863
[TBL] [Abstract][Full Text] [Related]
20. CD24 and S100A4 expression in resectable pancreatic cancers with earlier disease recurrence and poor survival.
Lee SH; Kim H; Hwang JH; Shin E; Lee HS; Hwang DW; Cho JY; Yoon YS; Han HS; Cha BH
Pancreas; 2014 Apr; 43(3):380-8. PubMed ID: 24622067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]